BIOMAT Database Logo BIOMAT Database Logo

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. 2008

H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Eye Research Center, Farabi Eye Hospital, Medical Sciences/University of Tehran and Ophthalmic Research Center, Noor Eye Hospital, Tehran - Iran.

OBJECTIVE To evaluate the additive effect of triamcinolone to bevacizumab in comparison to standard macular laser photocoagulation versus bevacizumab in the management of diabetic macular edema (DME). METHODS In a prospective, randomized clinical trial, 130 eyes of 110 patients with type 2 diabetes with DME were included. Eligible eyes were randomly assigned to 1.25 mg intravitreal bevacizumab (42 eyes) (IVB group) or combination of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide (41 eyes) (IVB+IVT group) or macular laser photocoagulation (47 eyes) (MPC). Central macular thickness (CMT) and visual acuity changes at week 6 and 16 were assessed. RESULTS The mean age of the patients was 57 -/+7 years. Patients were followed 16 weeks. At week 6, all the three groups showed significant reduction in CMT but the reductions for IVB and IVB+IVT were significantly more than MPC (p<0.001). At week 16, the response was not stable for IVB (p<0.001), but IVB+IVT maintained its superior status to MPC (p<0.001). At week 16, visual acuities were essentially unchanged for the two groups of MPC and IVB and improvement for IVB+IVT was marginal and at most was 0.1 log MAR. No patient developed uveitis, endophthalmitis, or thromboembolic event. CONCLUSIONS Single intravitreal bevacizumab or triamcinolone plus bevacizumab injection brought about significantly greater macular thickness reduction in diabetic patients in comparison to standard laser treatment. However, the response for bevacizumab alone was short-lived. Reduction in macular thickness was only marginally associated with visual acuity improvement in the triamcinolone plus bevacizumab injection group.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D008269 Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90) Central Retinal Edema, Cystoid,Cystoid Macular Edema,Macular Edema, Cystoid,Cystoid Macular Dystrophy,Cystoid Macular Edema, Postoperative,Irvine-Gass Syndrome,Macular Dystrophy, Dominant Cystoid,Edema, Cystoid Macular,Edema, Macular,Irvine Gass Syndrome,Syndrome, Irvine-Gass
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema.
October 2011, Korean journal of ophthalmology : KJO,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
June 2009, Ophthalmology,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
January 2007, Retina (Philadelphia, Pa.),
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema.
June 2008, The British journal of ophthalmology,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema.
September 2009, Korean journal of ophthalmology : KJO,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.
January 2013, International journal of ophthalmology,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema.
June 2013, Korean journal of ophthalmology : KJO,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular edema: a pilot study.
April 2012, Retina (Philadelphia, Pa.),
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema.
March 2007, Korean journal of ophthalmology : KJO,
H Faghihi, and R Roohipoor, and S-F Mohammadi, and K Hojat-Jalali, and A Mirshahi, and A Lashay, and N Piri, and Sh Faghihi
Intravitreal bevacizumab versus posterior subtenon triamcinolone in diffuse diabetic macular edema.
August 2015, International ophthalmology,
Copied contents to your clipboard!